Shuang Liu, PhD, Founder & CEO Co-inventor of CSTI-500. 20 years of experience in drug R&D as an integrated project leader. Led AMRI’s triple monoamine program and collaboration with a big pharma that delivered 4 NCEs, including CSTI-500, for clinical development. Led other successful discovery programs in CNS, oncology, and autoimmune at AMRI. Co-Inventor of >30 patent families. PhD in organic chemistry from the University of Georgia with postdoc training at Emory University.
Roman Dvorak, MD, PhD, Chief Medical Officer Over 25 years of clinical development, global regulatory leadership, and business development experience. Former CMO at Saniona where he led PWS and HO clinical trials of Tesomet. Also involved with Qnexa® & Meridia® clinical studies whilst holding senior roles at Vivus and Knoll, respectively. Roman has held other senior roles with Pfizer and J&J, and has specialist expertise in endocrinology & metabolic disorders.
Lois Rosenberger, PhD, Head of Regulatory President of LBR Regulatory and Clinical Consulting Services. 30+ years of regulatory, quality assurance, and 20+ years of experience in managing clinical trials including for PWS. Lois held regulatory leadership positions at Kendle CRO, Marion-Merrell Dow, and P&G.
William Bracken, PhD, DABT, Head of Toxicology Bill had near 30 years career at AbbVie as a member of the Preclinical Safety Leadership Team where he had scientific/regulatory management responsibilities for the early and late-stage drug development portfolio and marketed products. Bill’s accomplishments include published research in neurobiology, chemical carcinogenesis, hepatotoxicity, heavy metal toxicity, and toxicology in drug development.
John Maki, Strategic Advisor 30+ years of management and investment experience in life science. Formerly CEO of Vicus Therapeutics a clinical-stage immuno-oncology company, Managing Director at TDI and Audax Group, Principal at Bain Capital and Consultant at Bain & Company.